US FDA’s Preferred Special Treatment For Cannabinoids Points To Mistreating Industry

Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.